Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bellerophon Ther Com (BLPH)

Bellerophon Ther Com (BLPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Bellerophon Therapeutics: Q3 Earnings Snapshot

Bellerophon Therapeutics: Q3 Earnings Snapshot

BLPH : 0.0550 (+44.74%)
Bellerophon Therapeutics: Q1 Earnings Snapshot

Bellerophon Therapeutics: Q1 Earnings Snapshot

BLPH : 0.0550 (+44.74%)
Bellerophon Therapeutics: Q3 Earnings Snapshot

Bellerophon Therapeutics: Q3 Earnings Snapshot

BLPH : 0.0550 (+44.74%)
Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference

WARREN, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage...

BLPH : 0.0550 (+44.74%)
Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results

WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage...

BLPH : 0.0550 (+44.74%)
Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results

WARREN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage...

BLPH : 0.0550 (+44.74%)
Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference

WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage...

BLPH : 0.0550 (+44.74%)
Bellerophon Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Sarcoidosis

Phase 2 results provide clinically meaningful reduction in pulmonary vascular resistance; Company intends to design multi-dose Phase 2b trial Treatment...

BLPH : 0.0550 (+44.74%)
Bellerophon Therapeutics: Q3 Earnings Snapshot

WARREN, N.J. (AP) _ Bellerophon Therapeutics Inc. (BLPH) on Monday reported a loss of $4.6 million in its third quarter.

BLPH : 0.0550 (+44.74%)
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2021 Financial Results

WARREN, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage...

BLPH : 0.0550 (+44.74%)

Barchart Exclusives

IWM’s Unusual Options Activity Creates Opportunities for Small-Cap Investors
Although there wasn’t anything exciting to report from Wednesday’s unusual options activity, the iShares Russell 2000 ETF’s unusually active call options from yesterday suggest there are opportunities available for small-cap investors to make a buck over the long haul. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar